Edesa Biotech, Inc.

Listed Company

EDSACIK 0001540159NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsA1CAFY ends Sep 30

Period

FY 2025

Revenue

—

Net Income

$-7.20M

Total Assets

$13.53M

Equity

$12.45M

Shares Out

8.35M

Op. Cash Flow

$-7.30M

Business

Edesa Biotech, Inc. is a biopharmaceutical company developing therapies to treat inflammatory and immune-related diseases by acquiring, developing and commercializing clinical-stage drug candidates. It offers monoclonal antibodies, host-directed therapeutics and a topical non-steroidal cream—examples include EB06 (anti-CXCL10), EB05 (anti‑TLR4/paridiprubart) and EB01 (daniluromer cream). Its clinical pipeline is organized into two therapeutic areas: Medical Dermatology and Respiratory. The company conducts clinical trials and pursues regulatory approvals in the U.S., Canada, the EU and other jurisdictions and relies on third‑party CMOs, partners and licensing for development and distribution.

Summary from filing dated 2025-12-12

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30
Research and development	4	3	5	13	18
General and administrative	4	4	4	5	6
Loss from operations	−8	−7	−9	−18	−24
Reimbursement grant income	783,894	698,277	581,039	—	—
Interest income	2,558	153,498	289,846	63,523	11,165
Misc other income	0	14,766	0	—	—
Foreign exchange loss	−59,609	−21,042	−21,742	−21,114	−13,022
Nonoperating Income (Expense)	726,843	845,499	849,143	822,666	10
Loss before income taxes	−7	−6	−8	−18	−13
Income tax expense	800	800	800	800	800
Net loss	−7	−6	−8	−18	−13
Exchange differences on translation	76,842	−27,965	−1,046	−8,340	81,942
Net comprehensive loss	−7	−6	−8	−18	−13
Weighted average number of common shares (in shares)	6	3	3	—	—
Loss per common share - basic and diluted (in dollars per share)	−1.27	−1.93	−2.93	—	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30
Cash and cash equivalents	11	1	5	7	8
Accounts and other receivable	642,866	270,908	626,543	1	3
Prepaid expenses and other current assets	77,838	367,394	448,912	745,543	948,645
Total current assets	12	2	6	9	12
Long-term deposits	39,966	41,151	173,490	171,464	—
Intangible asset, net	2	2	2	2	2
Right-of-use assets	0	18,361	91,373	18,465	96,571
Total assets	14	4	9	12	15
Current liabilities:	1	2	2	2	1
Short-term right-of-use lease liabilities	0	19,867	74,714	18,975	78,808
Total current liabilities	1	2	2	2	1
Authorized unlimited common and preferred shares without par value issued and outstanding: 7,141,783 common shares (September 30, 2024 - 3,247,389)	55	47	47	—	35
Additional paid-in capital	15	14	13	11	5
Accumulated other comprehensive loss	−165,771	−242,613	−214,648	−213,602	−205,262
Accumulated deficit	−66	−59	−52	−44	−26
Total shareholders' equity	12	2	7	9	13
Total liabilities and shareholders' equity	14	4	9	12	15

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30
Depreciation and amortization	119,273	186,049	183,471	—	—
Share-based compensation	729,642	537,492	1	2	3
Gain on loan forgiveness	0	−14,766	0	—	—
Accounts and other receivable	−377,987	356,339	562,770	2	—
Prepaid expenses and other current assets	107,832	197,136	301,504	−19,497	—
Accounts payable and accrued liabilities	−715,499	17,590	−556,270	882,843	−124,724
Net cash used in operating activities	−7	−5	−7	−12	−14
Proceeds from issuance of common shares and warrants	8	729,387	4	12	41,981
Proceeds from issuance of Series A-1 preferred shares and warrants	2	0	—	—	—
Payment for issuance costs of warrants	−23,446	0	—	—	—
Repayment of debt	0	−29,532	0	—	—
Net cash provided by financing activities	17	592,031	5	12	14
Effect of exchange rate changes on cash and cash equivalents	46,216	−25,903	76,850	—	—
Net change in cash and cash equivalents	10	−4	−2	−748,340	625,564

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro